Sunitinib
Treatment for Kidney Cancer
Typical Dosage: 50 mg oral once daily (4 weeks on, 2 weeks off cycle)
Effectiveness
65%
Safety Score
30%
Clinical Trials
241
Participants
1.5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
30
DangerousModerateSafe
Treatment Details
Dosage Range
50 mg oral once daily (4 weeks on, 2 weeks off cycle)
Time to Effect
Weeks to months
Treatment Duration
Until disease progression or unacceptable toxicity (4 weeks on, 2 weeks off cycle)
Evidence Quality
HIGHConfidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$120,000
Monitoring:$15,000
Side Effect Mgmt:$10,000
Total Annual:$145,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$70,000/QALY
QALYs Gained
0.82
Outcome-Based Costs
Cost per Responder
$467,742
Cost per Remission
$7,250,000
Comparison vs Interferon-alpha
Cost Difference
+$50,000/year
More expensive
QALY Difference
+0.82 QALYs
Better outcomes
Dominance
No dominance
Sunitinib Outcomes
for Kidney Cancer
Efficacy Outcomes
Overall Effectiveness
+65%
Response Rate
+31%
Remission Rate
+2%
Common Side Effects
Fatigue
+65%
Diarrhea
+59%
Nausea
+44%
Mucositis/Stomatitis
+43%
Hand-foot syndrome
+40%
Hypertension
+31%
Sources:
Active Clinical Trials
1 active trial recruiting for Sunitinib in Kidney Cancer
A CpG-methylation-based Assay for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Treatment
NCT02688491NOT YET RECRUITINGNA
300 participants
INTERVENTIONAL
Started: Jul 1, 2016
Completed Clinical Trials
18 completed trials for Sunitinib in Kidney Cancer
Study to Evaluate Efficacy and Safety of Sunitinib in Renal Cell Carcinoma Progressed to 1L Immunotherapy Treatment.
NCT03066427COMPLETEDPHASE2
23 participants
INTERVENTIONAL
L'Hospitalet de Llobregat, Spain +8 more
Started: May 10, 2017
Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise Testing
NCT03109015COMPLETEDPHASE2
7 participants
INTERVENTIONAL
Durham, United States
Started: Sep 27, 2017
Dose-Finding Study Of CP-675,206 And SU011248 In Patients With Metastatic Renal Cell Carcinoma
NCT00372853COMPLETEDPHASE1
28 participants
INTERVENTIONAL
Scottsdale, United States +4 more
Started: Nov 1, 2006
Treatment Patterns With Targeted Therapies In Mrcc In Sweden - A Retrospective Analysis Of Data From National Registries
NCT04669366COMPLETED
1.21K participants
OBSERVATIONAL
Sollentuna, Sweden
Started: Jan 20, 2021
ELR+CXCL Cytokines in Metastatic Kidney Cancers: Predictive Markers of Resistance to Sunitinib
NCT03097601COMPLETED
60 participants
OBSERVATIONAL
Nice, France
Started: Jun 2, 2016
Sunitinib in Metastatic Renal Cancer
NCT01034878COMPLETEDPHASE2
25 participants
INTERVENTIONAL
Rozzano, Italy
Started: Dec 1, 2009
A Pivotal Study Of SU011248 In The Treatment Of Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma.
NCT00077974COMPLETEDPHASE2
106 participants
INTERVENTIONAL
Duarte, United States +14 more
Started: Feb 1, 2004
Perifosine + Sunitinib Malate for Patients With Advanced Cancers
NCT00399152COMPLETEDPHASE1
15 participants
INTERVENTIONAL
Started: Oct 1, 2006
A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer
NCT00375674COMPLETEDPHASE3
674 participants
INTERVENTIONAL
Los Angeles, United States +114 more
Started: Aug 1, 2007
Safety And Effectiveness Of Daily Dosing With 37.5 mg Sunitinib Malate In Patients With Advanced Kidney Cancer
NCT00338884COMPLETEDPHASE2
120 participants
INTERVENTIONAL
Córdoba, Argentina +14 more
Started: Sep 1, 2006
Special Investigation For Renal Cell Carcinoma (RCC) Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan)
NCT00716625COMPLETED
1.67K participants
OBSERVATIONAL
Started: Jun 1, 2008
Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma
NCT00706706COMPLETEDPHASE4
105 participants
INTERVENTIONAL
Guangzhou, China +10 more
Started: Jul 1, 2008
SU011248 In The Treatment Of Patients With Bevacizumab (Avastin)-Refractory Metastatic Renal Cell Carcinoma
NCT00089648COMPLETEDPHASE2
61 participants
INTERVENTIONAL
Duarte, United States +10 more
Started: Dec 1, 2004
Sunitinib Malate in Patients With Non-Clear Cell Renal Cell Cancer
NCT00465179COMPLETEDPHASE2
61 participants
INTERVENTIONAL
Houston, United States
Started: Mar 1, 2007
Palliative Radiofrequency Ablation in Metastatic Renal Cell Carcinoma Patients
NCT00891475COMPLETEDPHASE1, PHASE2
114 participants
INTERVENTIONAL
Moscow, Russia
Started: May 1, 2008
Sunitinib in Patients With Renal Cells Carcinoma Metastasic or Locally Avanced in Patients Not Candidates to Curative Previous Nefrectomy
NCT00663559COMPLETEDPHASE2
59 participants
INTERVENTIONAL
Barcelona, Spain +6 more
Started: Feb 1, 2008
Study of SU011248 in Patients With Advanced Kidney Cancer
NCT00254540COMPLETEDPHASE2
51 participants
INTERVENTIONAL
Akita, Japan +10 more
Started: Dec 1, 2005
Study In Patients With Kidney Cancer Treated With Sutent
NCT00873210COMPLETED
121 participants
OBSERVATIONAL
Banská Bystrica, Slovakia +13 more
Started: May 1, 2009
Showing 20 of 241 total trials